The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.
A user shared their positive experience with a hair transplant performed by Dr. Timothy Carman, using 1100 grafts via FUT surgery, and reported satisfaction with the results and minimal scarring. The user continues to use minoxidil and finasteride for hair maintenance.
The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.
The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.
The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.
A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.
The conversation is about comparing keratin hair fibers to Gossypium Herbaceum hair fibers for diffuse hair loss. The user prefers keratin fibers for their durability and is seeking a bulk purchase option.
The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.
The user had a hair transplant in May 2020 with 2000 grafts and has been using minoxidil and finasteride for maintenance. They are considering a second hair transplant for the crown area but are currently holding off.
User experienced significant hair regrowth using 1.25mg Finasteride daily and Nizoral once a week for 15 months. Noticeable results appeared after 6 months, with no side effects reported.
The user started using Hims Finasteride and Minoxidil topical in July 2023, added daily microneedling in November, and switched to chewable Finasteride and Minoxidil in January with increased microneedling frequency. They observed hair regrowth, suggesting diffuse thinning may be easier to treat.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
OP shared an 8-month update on hair transplant results, using Dutasteride, oral Minoxidil, and Biotin. OP also discussed a simple skincare routine with Cerave products and sunscreen.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.
The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.
PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.
Shedding stopped for a user after trying various hair loss treatments without success, including Propecia and Minoxidil. The improvement occurred after starting CB (possibly a hair loss treatment), Eucapil, natural sprays with rosemary and cloves, and regular sauna visits.
A user's 12 month update on treatment for hair loss, which include oral dutasteride and minoxidil, topical RU88541 and minoxidil, microneedling with hyaluronic acid and FinDuta, experiencing no side effects, positive results and inspiring other users.
The user switched from finasteride to dutasteride while continuing minoxidil and microneedling, seeing gradual hair regrowth. They are considering adding oral minoxidil and possibly a LLLT helmet for further improvement.
The user is dissatisfied with their hair transplant results from Asli Tarcan, citing poor donor area management and insufficient graft density. They advise against opting for cheaper procedures and express hope for future hair cloning solutions.
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.